MicroPharm Limited (“MicroPharm”) announced that it has secured a grant of £0.8M to further support the development of PolyCAb.  This is part of a grant totalling £2.1M from the UK’s innovation agency, the Technology Strategy Board, to a consortium led by MicroPharm comprising Public Health England (“PHE”) and University of Leeds.

 “PolyCAb has been developed for the treatment of acute Clostridium difficile infections (“CDI”) which are currently very difficult to treat,” said Ian Cameron, CEO of MicroPharm.  “CDI represent a significant healthcare burden globally with the elderly most at risk.  Our lead investigational candidate, which uses antibodies to bind to and neutralise the toxins the bacteria produce, has the potential to reduce recurrence and mortality rates amongst patients suffering from acute infections.”

 Professor John Landon, Chairman of MicroPharm said “We are very grateful for the support of the Biocatalyst fund from the TSB.  The grant enables MicroPharm and our partners to advance our novel therapeutic through to a Phase 2a clinical trial within a three year period.  This partnership brings together MicroPharm’s leading expertise in immunotherapy together with PHE’s expertise in recombinant toxins and the clinical expertise in CDI of Professor Mark Wilcox of the University of Leeds.”